Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 205 of 6351
-
New hope for Tough-to-Treat colorectal cancer: phase 3 trial launches
Disease control Recruiting nowColorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard of care (SOC) of LONSURF (trifluridine a…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
AI eye doctor: could software catch diabetic blindness sooner?
Diagnosis Recruiting nowTo validate the artificial intelligence subsystem of the DDART medical device for the automated detection of lesions compatible with diabetic retinopathy in a random sample of retinal fundus photographs. Secondary Objectives To determine the sensitivity and specificity of the ar…
Sponsor: Democritus University of Thrace • Aim: Diagnosis
Last updated Aug 13, 2026 00:00 UTC
-
New pill could ease juvenile arthritis in kids
Disease control Recruiting nowThis is a multicenter Phase 3, open-label, single-arm study to evaluate the safety, tolerability, PK, and efficacy of orally administered filgotinib for up to 18 weeks.
Phase 3 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New Pre-Surgery combo aims to shrink rectal tumors and save the rectum
Disease control Not yet recruitingThis study is for adults with locally advanced rectal cancer that has not spread to distant organs, and is classified as pMMR or MSS (which means it typically does not respond well to immunotherapy alone). The purpose is to see if a new combination of treatments given before surg…
Phase 2 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New cocktail aims to shrink untouchable liver tumors into surgical candidates
Disease control Recruiting nowPatients with hepatocellular carcinoma (HCC) complicated by Vp3 portal vein tumor thrombus (PVTT) face a poor prognosis and are typically ineligible for surgical resection. This prospective study evaluates a conversion therapy regimen-utilizing a combination of FOLFOX-HAIC, Lenva…
Phase 2 • Sponsor: First Hospital of China Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug duo aims to stop aggressive breast cancer's return
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate the efficacy and safety of sacituzumab tirumotecan (sac-TMT) sequential capecitabine versus single-agent capecitabine as adjuvant intensified therapy in patients with high-risk early-stage triple-negative breast cancer (TNBC) without…
Phase 3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Can a higher aspirin dose shield High-Risk pregnancies from preeclampsia?
Prevention Recruiting nowThe goal of this randomized clinical trial is to compare the effects of two doses of aspirin, 75 mg and 150 mg, in pregnant women who are at high risk of developing preeclampsia. The main question the study aims to answer is: 1. Does taking 150 mg of aspirin reduce the occurren…
Phase 4 • Sponsor: Medicare Hospital (Pvt) Limited • Aim: Prevention
Last updated Aug 23, 2026 00:00 UTC
-
New hope for bile duct cancer: experimental drug nanvuranlat in final testing
Disease control Recruiting nowThis study is designed to 1) select a dose regimen for continued development and 2) evaluate nanvuranlat versus Physicians Best Choice (PBC) (FOLFOX, FOLFIRI, or Best Supportive Care (BSC)) in participants aged 18 years and over with BTC. Participants enrolling in Part A the tria…
Phase 3 • Sponsor: J-Pharma Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
A steroid-sparing strategy: could olanzapine curb chemo nausea without the metabolic toll?
Symptom relief Recruiting nowThe aim of THE STUDY to determine whether an olanzapine-based dexamethasone-sparing antiemetic regimen is non-inferior to the standard dexamethasone-containing regimen in preventing delayed-phase Chemotherapy-induced nausea and vomiting while reducing metabolic toxicity in breast…
Sponsor: Alexandria University • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Can a new immunotherapy combo make stomach tumors disappear before surgery?
Disease control OngoingThis is a single-center, prospective, exploratory clinical study. Eligible patients will be enrolled and receive iapalolimab combined with DOS regimen (docetaxel + oxaliplatin + tegafur-gimeracil-oteracil potassium). The study aims to further explore the efficacy and safety of ia…
Phase 2 • Sponsor: Yongxu Jia • Aim: Disease control
Last updated Sep 10, 2026 01:00 UTC
-
Blood test may guide extra chemo to stop colon cancer return
Disease control Recruiting nowPhase III multicentric, open-label, randomized study The main objective is to assess the efficacy on time to disease recurrence (TTR) of treating minimal residual disease diagnosed by the presence of ctDNA after full treatment (surgery + chemotherapy) in stage III or high-risk s…
Phase 3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for Tough-to-Treat colon cancer: experimental drug combo enters final testing
Disease control Recruiting nowThis study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocen…
Phase 3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 10, 2026 01:00 UTC
-
Could a menstrual blood test replace surgery for endometriosis diagnosis?
Diagnosis Recruiting nowEndometriosis affects at least 1 in 10 women worldwide and is associated with a diagnostic delay of 5-10 years. Currently, definitive diagnosis requires invasive laparoscopy, which is costly and burdensome for patients. This multicenter diagnostic validation study investigates a…
Sponsor: Diamens FlexCo • Aim: Diagnosis
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo aims to outperform keytruda in head and neck cancer
Disease control Recruiting nowThis is a randomized, open-label, active-comparator-controlled, multi-regional, three-arm, phase 3 study comparing the efficacy and safety of ivonescimab in combination with ligufalimab to pembrolizumab and of ivonescimab alone to pembrolizumab as first-line treatment in patients…
Phase 3 • Sponsor: Groupe Oncologie Radiotherapie Tete et Cou • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Stem cell showdown: which transplant best keeps T-Cell cancer at bay?
Disease control Not yet recruitingTo evaluate, through a prospective multicenter observational study, autologous or allogeneic hematopoietic stem cell transplantation (Auto-SCT/allo-SCT)as consolidation therapy in subjects with T lymphoblastic leukemia/Lymphoblastic lymphoma(T-ALL/LBL)who have achieved first comp…
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for Drug-Resistant breast cancer: phase 3 trial launches
Disease control Recruiting nowThe study is being conducted to evaluate the efficacy and safety of HRS-8080 combined with dalpiciclib versus fulvestrant combined with dalpiciclib in patients with locally advanced/metastatic breast cancer who had developed drug resistance to prior adjuvant endocrine therapy.
Phase 3 • Sponsor: Shandong Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Triple threat: radiation plus Immuno-Chemo shows promise for lung cancer
Disease control Not yet recruitingThis is an open-label, randomized, controlled, multicenter phase III clinical trial designed to evaluate the efficacy and safety of spatially fractionated stereotactic body radiotherapy (SF-SBRT) combined with toripalimab and platinum-based chemotherapy versus toripalimab combine…
Phase 3 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can a One-Two punch wake up and destroy hidden HIV?
Disease control Not yet recruitingThis study aims to investigate the safety and preliminary efficacy of an innovative therapeutic strategy combining chidamide with NKG2D-directed chimeric antigen receptor natural killer (CAR-NK) cells in individuals living with HIV. The approach is predicated on the "shock and ki…
Phase 1/2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New combo therapy aims to shrink rectal tumors before Surgery—Could spare some patients the knife
Disease control Not yet recruitingStandard treatment for patients with proficient mismatch repair (pMMR) / microsatellite stable (MSS) locally advanced rectal cancer (LARC) consists primarily of neoadjuvant chemoradiotherapy followed by radical surgery. Several studies (including the UNION, STELLAR, TORCH, and SP…
Phase 2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug gilteritinib may beat standard therapy in preventing AML relapse after transplant
Disease control Recruiting nowThe study population consisted of FLT3-ITD-mutated AML patients who were FLT3-ITD-positive before allogeneic hematopoietic stem cell transplantation. This open-label, randomized, controlled trial enrolled participants and randomly assigned them in a 1:1 ratio to either the experi…
Phase 3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC